Dr reddy's laboratories ltd
RDY 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分優異，股利評分不錯，值得長期累積部位。若想獲得較好的進場時機，可參考技術面趨勢與波段評分
RDY 近期報酬表現
-0.56%
Dr reddy's laboratories ltd
-0.98%
同產業平均
-0.22%
S&P500
與 RDY 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
VTRS | Viatris inc | 4 分 | 2 分 | 2 分 | 3 分 | 4 分 | |
KPTI | Karyopharm therapeutics inc | 3 分 | 3 分 | 3 分 | 2 分 | 1 分 | |
RCKT | Rocket pharmaceuticals inc | 3 分 | 3 分 | 2 分 | 2 分 | 1 分 | |
NVS | Novartis ag | 3 分 | 1 分 | 2 分 | 2 分 | 5 分 | |
LGND | Ligand pharmaceuticals inc | 4 分 | 4 分 | 4 分 | 3 分 | 1 分 |
- VTRS Viatris inc價值 4 分趨勢 2 分波段 2 分籌碼 3 分股利 4 分查看更多
RDY 公司資訊
Dr. Reddy's Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.